# DaltonTx launches Dalton platform, partners with Sygnature > Source: > Published: 2026-06-04 08:51:56.303249+00:00 # DaltonTx launches Dalton platform, partners with Sygnature Per a GlobeNewswire press release distributed June 4, 2026 and republished by The Manila Times, DaltonTx announced the launch of **Dalton**, a drug discovery platform that the company describes as linking molecules, assays, models, experimental outcomes, project context and human decisions into a single learning system. The press release states **Dalton** supports the design-make-test-analyse cycle by integrating experimental data, predictive models, physics-based methods and AI agents into conversational workflows. DaltonTx also announced a collaboration with **Sygnature Discovery**, described in the release as a leading integrated drug-discovery CRO, which will use the Dalton platform to augment its computational and medicinal chemistry capabilities while safeguarding customer data. The announcement frames Dalton as a continuous learning engine intended to capture outcomes and decision rationale across discovery programmes. ### What happened Per a GlobeNewswire press release distributed June 4, 2026 and republished by The Manila Times, **DaltonTx** launched **Dalton**, a drug discovery platform that the release describes as an integrated, self-learning system linking molecules, assays, models, experimental outcomes, project context and human decisions. The press release states **Dalton** supports every step of the design-make-test-analyse cycle and integrates experimental data, predictive models, physics-based methods and AI agents into conversational workflows. The same release announces a collaboration with **Sygnature Discovery**, which the release identifies as a client that will use the Dalton platform to strengthen AI-enabled drug discovery workflows while safeguarding customer data. ### Technical details The press release positions **Dalton** as capturing both outcomes and the rationale behind human decisions, building what the company describes as organisational memory across discovery programmes. According to the release, the platform can plan analyses, orchestrate computational tools, compare modelling approaches and update models as new experimental data arrive. The release frames these capabilities as enabling scientists to surface suggestions on next steps and to reduce routine computational work. ### Industry context Editorial analysis: Companies integrating experimental data, modelling and decision logs into single platforms aim to shorten iteration loops in small-molecule and biologics discovery. Observed patterns in similar product launches show that vendors emphasise reproducible decision trails and model retraining workflows to support knowledge transfer across projects and teams. ### What to watch Editorial analysis: Observers should watch for third-party validations, benchmarked retrospective use cases, and published examples showing end-to-end gains in cycle time or hit rates. Also watch how DaltonTx handles data interoperability with common ELNs and LIMS and whether Sygnature publishes joint case studies demonstrating measurable impact. ### Caveats The details above are drawn from DaltonTx's press release as distributed via GlobeNewswire and republished by The Manila Times. The company has not provided independent benchmark data in the materials cited. ## Scoring Rationale A new AI-driven drug discovery platform with a CRO collaboration is notable for practitioners building discovery pipelines, but the announcement is a product launch without independent benchmarks. The story matters operationally but is not a sector-wide inflection. Practice interview problems based on real data 1,500+ SQL & Python problems across 15 industry datasets — the exact type of data you work with. [Try 250 free problems](/problems)